SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santen Pharmaceutical Co., Ltd. is a global pharmaceutical company specializing in ophthalmology. The company engages in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. Its portfolio addresses a wide range of ocular conditions, including glaucoma, dry eye, and infections. Serving patients, consumers, and medical professionals, Santen operates in over 60 countries and regions worldwide, guided by its vision of contributing to "Happiness with Vision" for people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:02
Registration Form
確認書
Japanese 8.7 KB
2025-11-10 07:01
Interim Report
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 366.6 KB
2025-10-15 03:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-09-12 04:58
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-08-13 03:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-15 04:38
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-25 04:08
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-24 09:22
Remuneration Information
臨時報告書
Japanese 32.1 KB
2025-06-23 08:29
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-23 08:28
Registration Form
確認書
Japanese 8.5 KB
2025-06-23 08:27
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 2.2 MB
2025-06-13 04:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-04-15 06:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB
2025-03-13 03:29
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-02-14 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.